IRIS UniCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.324
AS - Asia 9.273
EU - Europa 8.476
SA - Sud America 1.769
AF - Africa 256
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 6
Totale 29.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.945
SG - Singapore 4.476
DE - Germania 2.147
CN - Cina 2.019
IT - Italia 1.750
BR - Brasile 1.447
SE - Svezia 887
NL - Olanda 848
VN - Vietnam 820
FR - Francia 769
GB - Regno Unito 417
IE - Irlanda 391
IN - India 322
JP - Giappone 274
ID - Indonesia 272
HK - Hong Kong 233
FI - Finlandia 229
UA - Ucraina 222
RU - Federazione Russa 218
CA - Canada 181
PL - Polonia 138
KR - Corea 137
AR - Argentina 131
BD - Bangladesh 125
MX - Messico 122
TR - Turchia 120
IQ - Iraq 96
ES - Italia 91
ZA - Sudafrica 78
AT - Austria 65
PK - Pakistan 54
EC - Ecuador 50
BE - Belgio 47
SA - Arabia Saudita 39
CH - Svizzera 38
IR - Iran 38
CZ - Repubblica Ceca 37
LT - Lituania 35
VE - Venezuela 33
CO - Colombia 29
AE - Emirati Arabi Uniti 27
MA - Marocco 27
UZ - Uzbekistan 27
CI - Costa d'Avorio 26
EG - Egitto 26
PH - Filippine 25
KE - Kenya 24
PA - Panama 23
CL - Cile 22
IL - Israele 22
JO - Giordania 22
PY - Paraguay 21
RO - Romania 19
TN - Tunisia 18
RS - Serbia 17
OM - Oman 15
PE - Perù 14
BG - Bulgaria 13
MK - Macedonia 13
UY - Uruguay 13
KZ - Kazakistan 12
AU - Australia 11
CR - Costa Rica 11
DZ - Algeria 11
NP - Nepal 11
DO - Repubblica Dominicana 10
NG - Nigeria 10
PT - Portogallo 10
AL - Albania 9
AZ - Azerbaigian 9
DK - Danimarca 9
MY - Malesia 9
BY - Bielorussia 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
HU - Ungheria 7
TH - Thailandia 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
AM - Armenia 6
BO - Bolivia 6
ET - Etiopia 6
HR - Croazia 6
JM - Giamaica 6
LK - Sri Lanka 6
SN - Senegal 6
GE - Georgia 5
GR - Grecia 5
LB - Libano 5
LV - Lettonia 5
BH - Bahrain 4
HN - Honduras 4
NI - Nicaragua 4
SY - Repubblica araba siriana 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
EE - Estonia 3
GA - Gabon 3
LA - Repubblica Popolare Democratica del Laos 3
Totale 29.059
Salva come PNG Salva come JPEG
Città #
Singapore 2.658
Ashburn 1.130
San Jose 1.077
Chandler 1.008
Amsterdam 713
New York 437
Hefei 390
Dublin 356
Beijing 342
Rome 338
Los Angeles 316
Ho Chi Minh City 293
Frankfurt am Main 269
Tokyo 259
Jakarta 248
Milan 247
Lauterbourg 235
Hong Kong 208
Hanoi 198
Munich 178
Dallas 167
São Paulo 155
San Mateo 150
Boston 134
Seoul 132
Moscow 123
Jacksonville 122
Helsinki 113
Marseille 111
Chicago 110
Kent 110
Nanjing 100
Wilmington 96
Warsaw 94
Houston 91
Nürnberg 91
The Dalles 90
Buffalo 89
Santa Clara 89
Dearborn 78
Princeton 78
Orem 74
London 71
Ann Arbor 70
Nuremberg 70
Montreal 68
Woodbridge 66
Paris 62
Seattle 62
Atlanta 61
Council Bluffs 61
Brooklyn 60
Chennai 59
Denver 57
Stockholm 54
Johannesburg 52
Bremen 48
Da Nang 48
Poplar 48
Mexico City 47
Toronto 46
Baghdad 44
Düsseldorf 44
Fairfield 44
Nanchang 42
Phoenix 42
Brussels 39
Shanghai 38
Lappeenranta 37
Palermo 37
Pune 37
San Francisco 37
Belo Horizonte 36
Boardman 36
Rio de Janeiro 36
Redwood City 33
Ankara 32
Turku 32
Augusta 31
Brasília 31
Lawrence 31
Haiphong 29
Vienna 29
Hebei 27
Abidjan 26
Brno 26
Falkenstein 26
Lancaster 26
Biên Hòa 25
Bologna 25
Mumbai 25
New Delhi 25
Tianjin 25
Cattolica 24
City of London 24
Detroit 24
Dhaka 24
Manchester 24
Querétaro 24
Izmir 23
Totale 15.627
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 943
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 494
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 372
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 313
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 309
Cortical visual function in preterm infants in the first year. 275
Neurological examination of preterm infants a term equivalent age 269
Performance of Upper Limb module for Duchenne muscular dystrophy 232
Prognostic value of EEG performed at term age in preterm infants. 226
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 221
Assessing floppy infants: a new module 201
-Thalamic atrophy in infants with PVL and cerebral visual impairment 199
Crossed cerebellar atrophy of prenatal onset 198
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 189
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 187
Developmental milestones in type I spinal muscular atrophy 185
A current approach to heart failure in Duchenne muscular dystrophy 179
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 179
Visual development in prenatal post-haemorragic ventricular dilatation 178
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 176
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 174
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 174
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 169
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 169
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 165
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 164
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 163
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 163
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 162
Muscle MRI in Becker muscular dystrophy 162
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 162
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 160
Muscle MRI in Becker muscular dystrophy 159
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 158
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 158
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 154
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 154
Muscle MRI: Out of the tunnel. 154
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 152
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 152
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 152
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 152
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 151
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 150
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 150
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 149
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 148
Predominant distal muscle involvement in spinal muscular atrophy 147
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 147
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 146
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis 145
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 145
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 145
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 143
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 142
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 141
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 141
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 141
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 139
Congenital muscular dystrophies with cognitive impairment. A population study 137
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 137
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 136
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 136
Longitudinal assessments in discordant twins with SMA 136
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 136
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 134
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 134
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 133
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 133
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 133
6 minute walk test in duchenne MD patients with different mutations:12 month changes 133
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 133
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 132
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 131
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 131
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 130
MRI: Out of the tunnel. 130
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 130
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 130
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 130
Early treatment of type II SMA slows rate of progression of scoliosis 129
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 129
Emergencies cards for neuromuscular disorders 1st Consensus Meeting from UILDM - Italian Muscular Dystrophy Association Workshop report 128
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 128
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 127
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 126
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 126
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 125
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 125
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 124
Language Development in Preschool Duchenne Muscular Dystrophy Boys 124
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 124
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 123
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 123
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 123
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 123
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 122
Nusinersen in type 0 spinal muscular atrophy: should we treat? 122
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 121
Totale 16.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021125 0 0 0 0 0 0 0 0 0 30 90 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.141 302 385 205 465 198 400 221 281 398 60 147 79
2023/20242.651 114 471 102 179 106 410 354 102 52 131 270 360
2024/20255.462 124 100 405 245 458 262 230 242 782 421 1.221 972
2025/202614.298 1.773 538 1.054 1.899 2.791 1.855 2.367 645 758 618 0 0
Totale 29.506